Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Voyager Therapeutics, Inc. (VYGR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
3.7900-0.1200 (-3.07%)
At close: 4:00PM EDT
3.9300 +0.14 (+3.69%)
After hours: 07:59PM EDT
Advertisement

Voyager Therapeutics, Inc.

75 Sidney Street
Cambridge, MA 02139
United States
857 259 5340
http://www.voyagertherapeutics.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees177

Key Executives

NameTitlePayExercisedYear Born
Mr. Michael J. Higgins M.B.A.Interim CEO & Chairman90kN/A1962
Dr. Glenn F. PierceIndependent Director, Interim Chief Scientific Officer & Chief Medical Officer51.5kN/A1956
Mr. Robert W. HessleinSr. VP & Gen. Counsel580.65kN/A1953
Mr. G. Andre TurenneAdvisor873.48kN/A1974
Dr. Steven M. Paul M.D.Exec. Science Advisor & Director44kN/A1951
Dr. Krystof Bankiewicz M.D., Ph.D.FounderN/AN/AN/A
Dr. Guangping GaoFounderN/AN/AN/A
Dr. Mark A. Kay M.D., Ph.D.FounderN/AN/A1958
Dr. Phillip D. ZamoreFounderN/AN/AN/A
Ms. Allison DorvalCFO & Principal Accounting OfficerN/AN/A1976
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Voyager Therapeutics, Inc., a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia. The company has strategic collaboration agreements with the University of Massachusetts; and ClearPoint Neuro, Inc., as well as collaborations with Thermo Fisher Scientific and Fujifilm Diosynth Biotechnologies to support the development of its gene therapy programs. It also has a collaboration and license agreement with Neurocrine Biosciences, Inc. for the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Voyager Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement